Shield Therapeutics PLC (GB:STX)
LSE:STX
Top Page
Shield Therapeutics
(LSE:STX)
Select Model
Select Model
Rating:63Neutral
Price Target:
11.00 p
▲(11.68% Upside)
Action:ReiteratedDate:12/07/25
The overall stock score is primarily influenced by the company's robust technical momentum and positive corporate events, which are offset by significant financial challenges and valuation concerns. The strong technical indicators and strategic corporate developments provide optimism, but financial instability remains a critical risk.
Positive Factors
Strong revenue growth
Sustained, large revenue expansion demonstrates growing commercial traction for Accrufer and widening market adoption. A materially larger revenue base supports operating leverage potential, improves scale economics, and provides a more durable foundation for eventual margin recovery if cost control continues.
Negative Factors
Negative equity
Negative shareholders' equity reflects cumulative losses and weak capital structure, limiting the firm's ability to absorb shocks. It constrains borrowing capacity, raises insolvency risk, and typically necessitates equity raises or restructuring, which can dilute existing holders and hinder long-term strategic initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Sustained, large revenue expansion demonstrates growing commercial traction for Accrufer and widening market adoption. A materially larger revenue base supports operating leverage potential, improves scale economics, and provides a more durable foundation for eventual margin recovery if cost control continues.
Read all positive factors
Shield Therapeutics (STX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£87.61M
Dividend YieldN/A
Average Volume (3M)3.16M
Price to Earnings (P/E)―
Beta (1Y)1.58
Revenue Growth93.48%
EPS Growth51.18%
CountryUK
Employees63
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,068,418,500
10 Day Avg. Volume1,665,963
30 Day Avg. Volume3,163,002
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-23.24
Price to Sales (P/S)0.97
P/FCF Ratio-3.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£76.40M
Shield Therapeutics Business Overview & Revenue Model
Company Description
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral th...
How the Company Makes Money
Shield Therapeutics generates revenue through the sale of its core product, Accrufer, which is marketed to healthcare providers and institutions. The company employs a direct sales model as well as partnerships with distributors and wholesalers to...
Shield Therapeutics Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
28
Negative
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Jun 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.07M | 25.18M | 13.09M | 5.50M | 1.52M | 10.39M |
| Gross Profit | 14.32M | 10.57M | 4.03M | 2.00M | 539.00K | 9.03M |
| EBITDA | -9.93M | -16.58M | -30.29M | -46.07M | -17.69M | 820.00K |
| Net Income | -16.42M | -21.27M | -33.29M | -40.44M | -19.34M | -2.63M |
Balance Sheet | ||||||
| Total Assets | 62.10M | 45.90M | 48.80M | 22.07M | 44.41M | 32.53M |
| Cash, Cash Equivalents and Short-Term Investments | 10.81M | 5.61M | 13.95M | 2.82M | 12.12M | 2.94M |
| Total Debt | 27.05M | 21.06M | 20.41M | 6.10M | 156.00K | 28.00K |
| Total Liabilities | 76.96M | 46.95M | 26.49M | 16.65M | 3.38M | 2.25M |
| Stockholders Equity | -14.86M | -1.05M | 11.79M | 5.43M | 40.69M | 30.28M |
Cash Flow | ||||||
| Free Cash Flow | -8.15M | -7.03M | -40.07M | -20.14M | -18.80M | -1.42M |
| Operating Cash Flow | -8.15M | -7.01M | -37.13M | -18.25M | -16.74M | -1.40M |
| Investing Cash Flow | -1.30M | -1.89M | -2.43M | -1.70M | -2.05M | -20.00K |
| Financing Cash Flow | 11.83M | 4.21M | 49.66M | 7.71M | 27.58M | -47.00K |
Shield Therapeutics Technical Analysis
Negative
9.85
Price Trends
9.76
Negative
9.56
Negative
7.67
Positive
Market Momentum
-0.51
Negative
37.92
Neutral
57.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:STX, the sentiment is Negative. The current price of 9.85 is above the 20-day moving average (MA) of 8.64, above the 50-day MA of 9.76, and above the 200-day MA of 7.67, indicating a neutral trend. The MACD of -0.51 indicates Negative momentum. The RSI at 37.92 is Neutral, neither overbought nor oversold. The STOCH value of 57.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:STX.
Shield Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | £83.36M | -8.91 | -0.12% | ― | ― | ― | |
63 Neutral | £87.61M | -1.10 | 206.44% | ― | 93.48% | 51.18% | |
59 Neutral | £2.76B | 11.21 | 15.83% | 4.16% | 3.73% | 27.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | £664.92M | -9.44 | 227.10% | ― | -0.28% | 22.94% |
* Healthcare Sector Average
GB:STX
Shield Therapeutics
8.20
5.35
187.72%
GB:AGY
Allergy Therapeutics
10.50
4.00
61.54%
GB:HIK
Hikma Pharmaceuticals
1,273.00
-652.15
-33.88%
GB:VLG
Venture Life
68.25
27.25
66.46%
Shield Therapeutics Corporate Events
Regulatory Filings and Compliance
Shield Therapeutics Updates Market on Total Voting Rights and Share Capital
Neutral
Jan 30, 2026
Shield Therapeutics has announced that its issued share capital now comprises 1,067,997,016 ordinary shares of 1.5p each, all carrying equal voting rights and with no shares held in treasury. This updated total voting rights figure provides the ne...
Business Operations and StrategyProduct-Related Announcements
Shield Therapeutics Secures $7.9m China Milestone as ACCRUFeR® Nears NMPA Filing
Positive
Jan 30, 2026
Shield Therapeutics has updated the terms of its licensing agreement with Beijing Aosaikang Pharmaceutical for ACCRUFeR® in China, with ASK now expected to file for marketing authorisation with China’s NMPA in the first quarter of 2026,...
Business Operations and StrategyFinancial Disclosures
Shield Therapeutics Hits Q4 Cash Flow Positivity as ACCRUFeR Sales Jump 56% in 2025
Positive
Jan 21, 2026
Shield Therapeutics reported unaudited 2025 revenues of about $50 million, driven largely by a 56% surge in U.S. ACCRUFeR sales to roughly $46 million, underpinned by a 21% increase in average net selling price and a 33% rise in total prescription...
Regulatory Filings and Compliance
Shield Therapeutics Confirms Total Voting Rights and Share Capital Structure
Neutral
Jan 2, 2026
Shield Therapeutics has confirmed that its issued share capital comprises 1,067,828,251 ordinary shares, each carrying equal voting rights and with no shares held in treasury, establishing the official share count that investors must use when calc...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Shield Therapeutics Wins FDA Nod to Extend ACCRUFeR Use to Adolescents
Positive
Dec 22, 2025
Shield Therapeutics has secured U.S. Food and Drug Administration approval to extend the indication for its oral iron therapy ACCRUFeR (ferric maltol) to include pediatric patients aged 10 years and older, following a priority review supported by ...
Business Operations and StrategyDelistings and Listing Changes
Shield Therapeutics Announces Block Listing Application to London Stock Exchange
Positive
Dec 18, 2025
Shield Therapeutics has applied for a block listing of 15,000,000 ordinary shares to the London Stock Exchange, which will be allocated to the company’s Retention and Performance Share Plan and admitted to trading on 23 December 2025. The ap...
Business Operations and StrategyProduct-Related Announcements
Shield Therapeutics Wins Gold at Titan Branding Awards for ACCRUFeR®
Positive
Dec 11, 2025
Shield Therapeutics has been awarded Gold at the 2025 Titan Brand Awards for the rebranding of its product ACCRUFeR®, highlighting its effective brand strategy and communication in the competitive pharmaceutical market. This recognition under...
M&A TransactionsPrivate Placements and Financing
Shield Therapeutics Strengthens Financial Position with Amended Debt Financing
Positive
Dec 3, 2025
Shield Therapeutics has amended its senior secured debt financing, enhancing its financial position by increasing available funds to $50 million, with $15 million earmarked for future mergers and acquisitions. The revised terms, achieved through c...
Business Operations and StrategyProduct-Related Announcements
Shield Therapeutics Advances ACCRUFeR® Clinical Trials in Japan for PAH
Positive
Nov 14, 2025
Shield Therapeutics announced the initiation of a Phase II clinical trial in Japan for ACCRUFeR® (ferric maltol) as a treatment for Pulmonary Arterial Hypertension (PAH). This trial, conducted by its partner MEDLEAP Pharma, aims to support a ...
Business Operations and StrategyProduct-Related Announcements
Shield Therapeutics to Present Pediatric PK Results at ASH Conference
Positive
Nov 11, 2025
Shield Therapeutics announced the presentation of pediatric pharmacokinetic results for ferric maltol at the upcoming American Society of Hematology Conference. The study confirmed the suitability of ferric maltol for iron replacement in children,...
Business Operations and StrategyProduct-Related Announcements
Shield Therapeutics’ ACCRUFeR® Gains Approval in South Korea
Positive
Nov 7, 2025
Shield Therapeutics has announced that its product, ACCRUFeR®, has received marketing authorization from the Korean Ministry of Food and Drug Safety for treating iron deficiency in adults. This approval, following a successful pharmacokinetic...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.